Arbaclofen - Seaside Therapeutics
Alternative Names: R-baclofen; STX-209Latest Information Update: 28 May 2025
At a glance
- Originator Seaside Therapeutics
- Developer Seaside Therapeutics; The Childrens Hospital of Philadelphia; UMC
- Class Aminobutyric acids; Behavioural disorder therapies; Gastrokinetics; Muscle relaxants; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Fragile X syndrome
- Phase II Autism spectrum disorder
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-0 development in Autism spectrum disorder (In adolescents) in USA (PO, Fast dissolve)
- 18 Sep 2023 Allos Pharma has patent protection for arbaclofen in USA
- 18 Sep 2023 Allos Pharma plans a confirmatory phase III trial in Fragile X syndrome